The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes
Authors:
Open Access
- 1 August 2004
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (8) , 1915-1921
Abstract
OBJECTIVE—Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects and suppresses food intake in humans, but its therapeutic use is limited due to its short half-life. This was a randomized, double-blind, parallel-group, placebo-controlled trial investigating the effect of the long-acting GLP-1 derivative liraglutide (NN2211) on glycemic control, body weight, body composition, and 24-h energy expenditure in obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS—Thirty-three patients (mean ± SD) aged 60.0 ± 9.5 years, with HbA1c 7.5 ± 1.2% and BMI 36.6 ± 4.1 kg/m2, were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks. In addition to weight and glycemic parameters, body composition was assessed by dual-energy X-ray absorptiometry (DEXA) scanning and 24-h energy expenditure in a respiratory chamber. RESULTS—After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide, −1.90 mmol/l, and placebo, 0.27 mmol/l; P = 0.002) and HbA1c (liraglutide, −0.33%, and placebo, 0.47%; P = 0.028) compared with placebo. No change in body weight was detected (liraglutide, −0.7 kg, and placebo, −0.9 kg; P = 0.756). There was a nonsignificant trend toward a decrease in total fat mass (liraglutide, −0.98%, and placebo, −0.12%; P = 0.088) and toward an increase in lean body mass (liraglutide, 1.02%, and placebo, 0.23%; P = 0.118) in the liraglutide group compared with the placebo group. Twenty-four-hour energy expenditure was unaffected by the treatment (liraglutide, −12.6 kJ/h, and placebo, −13.7 kJ/h; P = 0.799). CONCLUSIONS—Eight weeks of 0.6-mg liraglutide treatment significantly improved glycemic control without increasing weight in subjects with type 2 diabetes compared with those on placebo. No influence on 24-h energy expenditure was detected.Keywords
This publication has 36 references indexed in Scilit:
- GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical developmentDrugs of the Future, 2001
- Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studiesInternational Journal of Obesity, 2000
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.International Journal of Obesity, 1999
- Glucagon-like peptidesDiabetes, 1998
- Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humansActa Physiologica Scandinavica, 1997
- Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitusEuropean Journal of Clinical Investigation, 1997
- Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDMDiabetes, 1996
- Attenuated GLP-1 secretion in obesity: cause or consequence?Gut, 1996
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987